ESLA Stock Catalyst: Estrella Immunopharma Treated First Patient with EB103 in STARLIGHT-1 Dose-Expansion Phase

Oct 15, 2026 · 2:36pm ET

The treatment involved two infusions of EB103.

Max move

+174.2%

High of day $0.85

Sparker timei

2:36pm ET

ESLA · Oct 15, 2026

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Estrella Immunopharma, Inc. (Nasdaq: ESLA) announced that it has treated the first patient with two infusions of EB103 in the dose-expansion phase of the STARLIGHT-1 trial.

The trial is evaluating the safety and efficacy of EB103, a gene-edited cell therapy, for the treatment of dystrophic epidermolysis bullosa (DEB).

Estrella Immunopharma has a free float of 15,139,440 shares.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time ESLA sparks.

Download Sniper App →

Catch the next ESLA-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →

Every Second Counts.Don't Trade Without a Real-Time sparker alert.

ESLA Stock Catalyst: Estrella Immunopharma Treated First Patient with EB103 in STARLIGHT-1 Dose-Expansion Phase

ESLA · Oct 15, 2026

ESLA · Oct 15, 2026

Every Second Counts.
Don't Trade Without a Real-Time sparker alert.